Literature DB >> 309134

Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor.

M S Read, R W Shermer, K M Brinkhous.   

Abstract

A platelet-aggregating activity was found in many snake venoms, predominantly those of the genus Bothrops, that is apparent only in the presence of the platelet-aggregating von Willebrand factor of plasma. It is designated "venom coagglutinin." The coagglutinin can be largely separated from the thrombin-like enzyme of the venoms by ion-exchange chromatography. The venom factor acts on formaldehyde-fixed platelets and is effective with decalcified, heparinized, and afibrinogenemic plasmas but not with severe von Willebrand disease plasmas or with normal plasmas in which the von Willebrand factor has been neutralized by specific antibodies. Use of this coagglutinin permits the assay of von Willebrand factor without the many disadvantages of the ristocetin test. The coagglutinin is active with human, dog, pig, and bovine plasmas and with platelets of any one of these species. This broad-spectrum activity without regard to species contrasts with the ristocetin-resistance of many combinations of plasma and platelets from various species. The assay provides a procedure for studying human, porcine, and canine von Willebrand disease. The lack of species specificity of the coagglutinin suggests that it may be a universal activator of the von Willebrand factor-platelet reaction.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309134      PMCID: PMC336146          DOI: 10.1073/pnas.75.9.4514

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  11 in total

1.  Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test.

Authors:  K M Brinkhous; J E Graham; H A Cooper; J P Allain; R H Wagner
Journal:  Thromb Res       Date:  1975-03       Impact factor: 3.944

2.  Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.

Authors:  J P Allain; H A Cooper; R H Wagner; K M Brinkhous
Journal:  J Lab Clin Med       Date:  1975-02

3.  Nature of von Willebrand factor: a new assay and a specific inhibitor.

Authors:  K E Sarji; R D Stratton; R H Wagner; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

4.  Plasma levels of platelet aggregating factor/vom Willebrand factor in various species.

Authors:  K M Brinkhous; B D Thomas; S A Ibrahim; M S Read
Journal:  Thromb Res       Date:  1977-09       Impact factor: 3.944

Review 5.  The platelet: membrane and surface reactions.

Authors:  H A Cooper; R G Mason; K M Brinkhous
Journal:  Annu Rev Physiol       Date:  1976       Impact factor: 19.318

6.  Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.

Authors:  P M Blatt; K M Brinkhous; H R Culp; J S Krauss; H R Roberts
Journal:  JAMA       Date:  1976-12-13       Impact factor: 56.272

7.  Platelet-aggregating factor and the aggregation of fixed washed platelets.

Authors:  H A Cooper; K W Wilkins; P R Johnson; R H Wagner
Journal:  J Lab Clin Med       Date:  1977-09

8.  Antibody nature of circulating inhibitor of plasma von Willebrand factor.

Authors:  R D Stratton; R H Wagner; W P Webster; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

9.  Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.

Authors:  H J Weiss; L W Hoyer; F R Rickles; A Varma; J Rogers
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  Von Willebrand factor: gene dosage relationships and transfusion response in bleeder swine--a new bioassay.

Authors:  T R Griggs; W P Webster; H A Cooper; R H Wagner; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

View more
  22 in total

Review 1.  Factor VIII/von Willebrand factor: a multivalent ligand binding to platelets and collagen.

Authors:  M Furlan
Journal:  Blut       Date:  1986-06

2.  Primary structure of two-chain botrocetin, a von Willebrand factor modulator purified from the venom of Bothrops jararaca.

Authors:  Y Usami; Y Fujimura; M Suzuki; Y Ozeki; K Nishio; H Fukui; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

3.  Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface.

Authors:  S J Shattil; J S Bennett; M McDonough; J Turnbull
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

Review 4.  Animal models of hemophilia and related bleeding disorders.

Authors:  Jay N Lozier; Timothy C Nichols
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 5.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

6.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site.

Authors:  K Ravid; T Doi; D L Beeler; D J Kuter; R D Rosenberg
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

8.  O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b.

Authors:  J A Carew; S M Quinn; J H Stoddart; D C Lynch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

9.  Lessons Learned from Animal Models of Inherited Bleeding Disorders.

Authors:  Timothy C Nichols
Journal:  Hematol Educ       Date:  2014-06

10.  A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected].

Authors:  H R Gralnick; S Williams; L McKeown; W Kramer; H Krutzsch; M Gorecki; A Pinet; L I Garfinkel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.